Literature DB >> 25179012

CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro.

Igor Tsaur1, Jochen Rutz, Jasmina Makarević, Eva Juengel, Kilian M Gust, Hendrik Borgmann, David Schilling, Karen Nelson, Axel Haferkamp, Georg Bartsch, Roman A Blaheta.   

Abstract

PURPOSE: Chemokines undergo alterations during neoplasia. However, knowledge about their functional significance in prostate cancer (PCa) progression is still sparse. Since chemokine (C-C motif) ligand 2 (CCL2) is significantly up-regulated in patients with PCa, aim of the current study was to assess whether CCL2 contributes to invasive behavior of prostate cancer cells in vitro.
METHODS: The human PCa cell line PC3 was stimulated with CCL2. Cell growth was investigated by MTT dye reduction assay. Cell adhesion was analyzed by measuring attachment to a human endothelial cell (HUVEC) monolayer and immobilized collagen. Cell migration was assessed by a chemotactic assay. Integrin expression on the cell surface was evaluated by Western blot. Blocking studies were performed with anti-integrin α3, anti-integrin α6 and anti-integrin β4 monoclonal antibodies.
RESULTS: PC3 cell growth 72 h after CCL2 exposure was significantly increased, compared to controls. Activation of tumor cells by CCL2 significantly enhanced tumor cell adhesion to HUVEC and immobilized collagen. CCL2, added for 4 or 24 h, elevated α6 and β4 (4 > 24 h) integrin expression. α3 was enhanced after 4 h, but reduced after 24 h. Blocking either α3, α6 or β4 led to significant suppression of tumor cell binding to immobilized collagen.
CONCLUSIONS: CCL2 stimulates PCa cell adhesion and induces alterations in α3-, α6- and β4-integrin expression on the cell surface. Blocking these integrins leads to a significant reduction in cell adhesion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25179012     DOI: 10.1007/s00345-014-1389-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  33 in total

Review 1.  Role of integrins in cell invasion and migration.

Authors:  John D Hood; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

Review 2.  Chemokines: agents for the immunotherapy of cancer?

Authors:  Bernhard Homey; Anja Müller; Albert Zlotnik
Journal:  Nat Rev Immunol       Date:  2002-03       Impact factor: 53.106

3.  An economic analysis of conservative management versus active treatment for men with localized prostate cancer.

Authors:  Daniella J Perlroth; Jay Bhattacharya; Dana P Goldman; Alan M Garber
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

4.  CCL2 is a potent regulator of prostate cancer cell migration and proliferation.

Authors:  Robert D Loberg; LaShon L Day; Jason Harwood; Chi Ying; Lauren N St John; Ryan Giles; Chris K Neeley; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

5.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Authors:  Xin Li; Robert Loberg; Jinhui Liao; Chi Ying; Linda A Snyder; Kenneth J Pienta; Laurie K McCauley
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 6.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

Review 7.  CXC chemokines in angiogenesis of cancer.

Authors:  Robert M Strieter; John A Belperio; Roderick J Phillips; Michael P Keane
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

8.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

9.  Specific alterations in the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane.

Authors:  S Dedhar; R Saulnier; R Nagle; C M Overall
Journal:  Clin Exp Metastasis       Date:  1993-09       Impact factor: 5.150

10.  The integrin alpha6beta4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures.

Authors:  I Rabinovitz; A M Mercurio
Journal:  J Cell Biol       Date:  1997-12-29       Impact factor: 10.539

View more
  5 in total

1.  CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway.

Authors:  Hiroaki Yasui; Hiroaki Kajiyama; Satoshi Tamauchi; Shiro Suzuki; Yang Peng; Nobuhisa Yoshikawa; Mai Sugiyama; Kae Nakamura; Fumitaka Kikkawa
Journal:  Clin Exp Metastasis       Date:  2019-09-21       Impact factor: 5.150

2.  Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis.

Authors:  Li Zhang; Longjiang Shao; Chad J Creighton; Yiqun Zhang; Li Xin; Michael Ittmann; Jianghua Wang
Journal:  Oncotarget       Date:  2015-03-20

3.  Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer.

Authors:  Martin Lund; Torben B Pedersen; Søren Feddersen; Louise D Østergaard; Charlotte A Poulsen; Christian Enggaard; Mads H A Poulsen; Lars Lund
Journal:  Res Rep Urol       Date:  2022-02-11

Review 4.  The Exploration of Chemokines Importance in the Pathogenesis and Development of Endometrial Cancer.

Authors:  Jakub Dobroch; Klaudia Bojczuk; Adrian Kołakowski; Marta Baczewska; Paweł Knapp
Journal:  Molecules       Date:  2022-03-22       Impact factor: 4.411

5.  Effect of chemokine CC ligand 2 (CCL2) on α‑synuclein‑induced microglia proliferation and neuronal apoptosis.

Authors:  Lijun Zhang; Pengju Ma; Qingkai Guan; Lei Meng; Linlin Su; Lina Wang; Bin Yuan
Journal:  Mol Med Rep       Date:  2018-09-10       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.